Wegovy HD 7.2mg Just Got FDA Approved: The Strongest Semaglutide Injection Yet

On March 19, 2026, the FDA approved Wegovy HD — a 7.2mg dose of semaglutide that delivers the highest weight loss ever seen from a Wegovy injection. The approval came in just 54 days under the new National Priority Voucher program, making it the fastest GLP-1 approval in history.

This isn't a new drug. It's a higher dose of the semaglutide you already know — three times the standard 2.4mg maintenance dose. And for patients who've plateaued on the current dose, it could be exactly the step-up they've been waiting for.

The STEP UP Trial Results

The approval is based on the Phase 3b STEP UP trial, which enrolled 1,407 adults with obesity (BMI 30+) without diabetes. Participants were randomly assigned to Wegovy 7.2mg, Wegovy 2.4mg, or placebo for 72 weeks.

From a mean starting weight of 248 lbs, patients on the 7.2mg dose lost an average of 51 pounds. Nearly a third lost over 62 pounds. These numbers put Wegovy HD in the same territory as Zepbound 15mg (tirzepatide), which has shown approximately 20-21% weight loss in trials.

Who Is Wegovy HD For?

Wegovy HD is not a starting dose. The FDA label is specific: it's for adults with obesity who have already tolerated the 2.4mg dose for at least 4 weeks and for whom additional weight reduction is clinically indicated.

In practical terms, this means patients who:

• Are already on Wegovy 2.4mg and have plateaued
• Haven't reached their clinically meaningful weight loss target
• Tolerate the current dose without significant side effects
• Want additional weight reduction before considering other interventions

The 20-week dose escalation starts at 0.25mg and steps through the standard titration before reaching 7.2mg. If you're already at 2.4mg, your provider can escalate directly to 7.2mg after confirming tolerability.

Side Effects: What's New at the Higher Dose

The most common side effects — nausea, vomiting, constipation, abdominal pain — are consistent with lower doses and occurred primarily during titration. The overall discontinuation rate for GI side effects was low at 3.3%.

One new finding: dysesthesia (altered skin sensations like tingling, numbness, or hypersensitivity) was reported at a higher rate with 7.2mg than with 2.4mg or placebo. Novo Nordisk has added this to the label. It was mostly mild, but patients should know to watch for unusual skin sensations and discuss them with their provider.

Hair loss was also listed among common adverse reactions — consistent with the rapid weight loss seen in the trial, not a direct drug effect.

The National Priority Voucher: What Just Happened

Wegovy HD is the first GLP-1 approved under the FDA's new Commissioner's National Priority Voucher pilot program. This program fast-tracks products that address critical national health priorities. The review took just 54 days — compared to the typical 10-12 month timeline.

FDA Commissioner Martin Makary called it a demonstration of what the FDA “can accomplish when we try bold new things.” Both Wegovy HD and Eli Lilly's orforglipron received vouchers tied to pricing commitments for Medicare and Medicaid programs.

How Wegovy HD Fits the Full Product Lineup

With this approval, the Wegovy family now includes three formulations:

Wegovy HD will be available through the same channels as existing Wegovy formulations: 70,000+ US pharmacies (including CVS and Costco), select telehealth providers, NovoCare Pharmacy, and GoodRx. Coverage and savings information will be available at launch.

What About Patients on Compounded Semaglutide?

For patients currently using compounded semaglutide at higher-than-standard doses, Wegovy HD offers a legitimate FDA-approved pathway. If your compounding pharmacy has been dosing above 2.4mg, the 7.2mg branded option now provides a regulated, quality-controlled alternative at a dose your body is already accustomed to.

Novo Nordisk has not announced specific pricing for Wegovy HD. It's expected to be priced similarly to existing Wegovy injections, with savings card programs for eligible patients.

The Bottom Line

Wegovy HD closes the efficacy gap between semaglutide and tirzepatide. At 20.7% weight loss, it matches Zepbound's results — and for patients already responding well to semaglutide, it offers a path to stronger results without switching drug classes.

If you're on Wegovy 2.4mg and have plateaued, talk to your provider about whether the 7.2mg dose makes sense for your goals. It launches in April 2026.